

NEW STRATEGY FOR TREATMENT OF NEURODEGENERATIVE DISEASES WITH AXONOPATHY

<u>DiAntonio, Aaron, Geisler, Stefanie, Mao, Xianrong, Milbrandt, Jeffrey, Summers, Daniel</u> Gill, John

T-017543


Value Proposition: This invention uses a novel gene therapy that blocks the axon degeneration typical of neurodegenerative diseases.

Technology Description

Researchers at Washington University in St. Louis have developed a new strategy for treatment of neurodegenerative diseases with axonopathy. Axon loss is a central element of many types of neurodegenerative diseases including but not limited to peripheral neuropathy, glaucoma, traumatic brain injury, ALS, Parkinson's Disease, MS, and Alzheimer's Disease. SARM1 is an NAD+ cleaving enzyme that is the central executioner of the axon degeneration pathway. Currently, there is no practical method to inhibit SARM1 in patients.

This strategy uses a potent SARM1 dominant negative gene therapy, that blocks SARM1 activity and prevents axon degeneration, to treat neurodegenerative diseases in which axon degeneration is a major component of disease symptomatology.

SARM1



Stage of Research

The research team has demonstrated that SARM1 dominant negatives K193R, H685A, and combined K193/H685A have the most potent effect in blocking axon degeneration in an in vitro model of axon degeneration in DRG neurons.

Applications

Treatment of neurodegenerative diseases

Key Advantages

• Stops axon degeneration typical of neurodegenerative diseases



Patents:

- Issued Patent, <u>JP73679882</u>
- Additional application pending

Related Web Links - <u>Aaron DiAntonio Profile</u>; <u>DiAntonio Lab</u>